树突状细胞瘤苗治疗新诊断的胶质母细胞瘤的疗效：一项随机对照研究的荟萃分析。
The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma: A meta-analysis of randomized controlled studies.
机构信息
Department of neurosurgery, the general hospital of Ningxia Medical University, Ningxia, China.
Ningxia Medical University, Ningxia, China.
出版信息
Neurochirurgie. 2021 Sep;67(5):433-438. doi: 10.1016/j.neuchi.2021.04.011. Epub 2021 Apr 26.
INTRODUCTION
The efficacy of dendritic cell vaccine to treat glioblastoma remained elusive and therefore we conducted a meta-analysis to explore the influence of dendritic cell vaccine on treatment efficacy of glioblastoma.
METHODS
PubMed, EMbase, Web of science, EBSCO and Cochrane library databases have been searched through October 2020, and we included randomized controlled trials (RCTs) assessing the efficacy of dendritic cell vaccine for glioblastoma.
RESULTS
Four RCTs and 267 patients were included in the meta-analysis. Compared to control group for glioblastoma, dendritic cell vaccine demonstrated no obvious impact on overall survival (HR=0.59; 95% CI=0.34 to 1.04; P=0.07), progression-free survival (PFS, HR=0.72; 95% CI=0.52 to 1.00; P=0.05), nervous system disorders (OR=0.61; 95% CI=0.29 to 1.29; P=0.20), or adverse events (OR=1.44; 95% CI=0.82 to 2.50; P=0.20).
CONCLUSIONS
Dendritic cell vaccine may be not effective to treat glioblastoma.
简介
树突状细胞疫苗治疗脑胶质瘤的疗效仍不明确，因此我们进行了一项荟萃分析，以探讨树突状细胞疫苗对脑胶质瘤治疗效果的影响。
方法
检索了 PubMed、EMbase、Web of science、EBSCO 和 Cochrane library 数据库，截至 2020 年 10 月，纳入评估树突状细胞疫苗治疗脑胶质瘤疗效的随机对照试验（RCT）。
结果
荟萃分析纳入了 4 项 RCT 和 267 名患者。与脑胶质瘤对照组相比，树突状细胞疫苗对总生存期（HR=0.59；95%CI=0.34 至 1.04；P=0.07）、无进展生存期（PFS，HR=0.72；95%CI=0.52 至 1.00；P=0.05）、神经系统疾病（OR=0.61；95%CI=0.29 至 1.29；P=0.20）或不良事件（OR=1.44；95%CI=0.82 至 2.50；P=0.20）无明显影响。
结论
树突状细胞疫苗治疗脑胶质瘤可能无效。
Zotero 插件